内侧半月板后角退行性撕裂:MRI表现与关节腔内类固醇/布比卡因注射后结局的相关性
研究纳入60例有症状的内侧半月板后角退行性撕裂患者,均已保守治疗失败,接受影像引导下膝关节腔内类固醇/布比卡因注射并随访至少6个月。49/60例(82%)症状改善(完全缓解25例,部分缓解24例),32/60例(53%)随访时改善持续。孤立性撕裂者18例中13例(72%)完全缓解,随访时10例(56%)持续。结论认为注射可减轻多数患者疼痛,术前MRI表现与注射反应相关,孤立性撕裂者更可能获得良好结局。
要点
- 内侧半月板后角退行性撕裂患者关节腔内类固醇/布比卡因注射后82%症状改善。
- 孤立性撕裂者完全缓解率72%,高于整体完全缓解率42%。
- 术前MRI表现与注射后临床反应相关,孤立性撕裂提示预后更好。
核心结论
- 关节腔内类固醇/布比卡因注射可减轻多数(81.7%)内侧半月板后角退行性撕裂患者的疼痛症状,且通常反应持续。
- 术前MRI表现与注射反应相关,孤立性撕裂患者更可能获得良好结局。
研究设计与样本
- 研究纳入60例有临床和MRI证据的内侧半月板后角有症状退行性撕裂患者,撕裂可为孤立性或伴退行性关节炎其他表现,且均已保守治疗(物理治疗、非甾体抗炎药、3个月休息/膝关节支具)失败。
- 患者接受膝关节腔内类固醇/布比卡因注射,临床随访至少6个月。
- 将术前MRI表现与症状持续时间、注射后临床反应(记录为完全、部分或无反应)及反应持续时间进行相关性分析。
诊断标准与关键数值
- 49/60例(82%)报告注射后症状改善,其中完全缓解25例(42%),部分缓解24例(40%)。
- 32/60例(53%)在随访时改善持续。
- 18例孤立性内侧半月板后角退行性撕裂中13例(72%)记录到症状完全缓解,随访时10例(56%)持续。
临床应用与阅片要点
- 术前MRI显示孤立性内侧半月板后角退行性撕裂者,关节腔内类固醇/布比卡因注射后更可能获得完全且持续的缓解。
- 术前MRI表现可用于预估注射治疗的反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the response of symptomatic degenerative tears of the posterior horn of the medial meniscus to guided intra-articular knee steroid/bupivacaine injection and to correlate clinical outcomes with preprocedural findings at magnetic resonance imaging (MRI).
MATERIALS AND METHODS: Sixty patients who had clinical and MRI evidence of a symptomatic degenerative tear of the posterior horn of the medial meniscus, isolated or accompanied by additional features of degenerative arthritis, who had failed conservative approaches (physiotherapy, non-steroidal anti-inflammatories, and 3 months rest/knee bracing) were included in the study. Patients underwent intra-articular knee steroid/bupivacaine injection and were followed clinically for a minimum of 6 months. Preprocedural MRI findings were correlated with duration of symptoms, clinical response to injection (recorded as complete, partial or no response) and duration of response to injection.
RESULTS: Forty-nine of 60 patients (82%) reported an improvement in symptoms following guided intra-articular knee steroid/bupivacaine injection (complete: 25 patients (42%), partial: 24 (40%) patients). Improvement was sustained in 32 of 60 patients (53%) at follow-up. Thirteen of 18 patients (72%) who had an isolated degenerative tear of the posterior horn of the medial meniscus recorded a complete resolution of symptoms. This was sustained at follow-up in 10 patients (56%).
CONCLUSION: Intra-articular steroid/bupivacaine knee joint injection reduced pain symptoms in the majority of patients (81.7%) with degenerative tears of the posterior horn of the medial meniscus, usually with a sustained response. Preprocedural MRI appearances correlate with response to injection. Patients with isolated tears are more likely to have a favourable outcome.
引用
- Byrne C, Alkhayat A, Bowden D, et al. Degenerative tears of the posterior horn of the medial meniscus: correlation between MRI findings and outcome following intra-articular steroid/bupivacaine injection of the knee. Clin Radiol. 2019. PMID: 30914206. doi:10.1016/j.crad.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。